Tvardi's TTI-101 breast cancer trial posts results after early terminationSep 24Trial updateTTI-101Tvardi Therapeutics, Incorporated
Tvardi reports healthy volunteer data for TTI-109, picks ulcerative colitis as lead indicationAug 14Quarterly updateTvardi Therapeutics, Incorporated
Tvardi selects ulcerative colitis as first indication for TTI-109, sets KOL webinarJul 30Regulatory decisionTvardi Therapeutics, Incorporated
Tvardi Therapeutics files for up to $9.7 million more in at-the-market stock salesJul 17FinancingTvardi Therapeutics, Incorporated
Tvardi's TTI-109 Phase 1 study confirms prodrug design and STAT3 target engagementJul 7Clinical readoutTTI-101Tvardi Therapeutics, Incorporated
